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few CEDs (8%) for which there were SEP (e.g. monitoring of HbA1c for antidiabetics 
in Italy). ConClusions: Although SEP are considered as not reliable from payers’ 
perspective to fund newly approved products, they have become widely acceptable 
for defining success criteria in P4P. This highlights the limitation of P4P, and more 
research would be needed to assess the actual predictive value of such endpoints. 
On the opposite, CED appears to be an appropriate tool to address payers’ uncer-
tainty as they rely on HEP for decision making.
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objeCtives: Decision makers in middle income countries are using pharma-
coeconomics studies (PEs) and health technology assessments (HTAs) in pricing 
and reimbursement decisions. However, whilst many of these jurisdictions have 
local submission guidelines and local expertise, the studies themselves often use 
models developed elsewhere and elements of data from countries other than the 
jurisdiction concerned. The objectives of this study were to assess the challenges 
faced by decision makers in transferring pharmacoeconomic data and analyses 
from other jurisdictions. Methods: We conducted an interview survey of repre-
sentatives of decision making bodies from jurisdictions in Asia, Central and Eastern 
Europe, and Latin America that had at least one year’s experience of using PEs and 
HTAs. Results: Representatives of the relevant organizations in 12 countries were 
interviewed. All 12 jurisdictions had developed official guidelines for the conduct of 
HTAs or PEs. All but one of the organizations evaluated studies submitted to them, 
but 9 also conducted studies and 7 commissioned them. Nine of the organizations 
stated that, in evaluating HTAs or PEs submitted to them, they had consulted a 
study performed in a different jurisdiction. Data on relevant treatment effect was 
generally considered more transferable than those on prices/unit costs. Views on 
the transferability of epidemiological data, data on resource use and health state 
preference values were more mixed. Eight of the respondents stated that analyses 
submitted to them had used models developed in other jurisdictions. Four of the 
organizations had a policy requiring models to be adapted to reflect local circum-
stances. ConClusions: Decision makers in middle income countries were facing 
several challenges in transferring data or studies, mainly due to differences in cur-
rent standard of care, practice patterns or GDP between the developed countries 
where the majority of the studies are conducted and their own jurisdiction.
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bACkgRound: GWAS can identify targets of marketed drugs that are strongly asso-
ciated with disease(s) different from approved indication, providing opportunities 
to substantially shorten the drug development process by repositioning the drug as 
treatment for the newly identified disease, potentially yielding substantial socio-
economic benefits. objeCtives: To estimate economic benefits of repositioning 
three drugs to GWAS-identified diseases Methods: GWAS were used to identify 
denosumab (currently for osteoporosis) as possible treatment for Crohn’s disease, 
melatonin (circadian adjustment) for diabetes, and niacin (lipid-lowering) for aortic 
stenosis (AS). Economic models were constructed for the three illnesses--using data 
from Canadian registries, claims databases and clinical trials--comparing current 
management of the target illness with use of the repositioned drug. Costs (2013 CAD) 
were obtained from Medicare, Ontario Case Costing Project and price lists. Analyses 
covered each province and Canada. Results: In all three cases, the repositioned 
product was dominant over current treatment mix, even at relatively low levels of 
uptake (> 5%). With 50% uptake, in Crohn’s, denosumab would provide substan-
tial reductions in side-effects and savings of $1,619/pt, resulting in $161 million in 
annual savings across Canada; in diabetes, melatonin would save $205/pt annu-
ally, or more than $365 million for Canada, assuming equal efficacy; in AS, niacin 
would save $4.5 million in Quebec alone, largely by averting valve replacement 
surgery, providing additional benefits via reduced associated morbidity and mortal-
ity. Extensive sensitivity analyses showed these results to remain directionally the 
same except at extremely low rates of uptake or with significant increases in the 
price of the repositioned product. ConClusions: Using GWAS data to reposition 
existing drugs to other diseases offers sizeable reductions in the cost and time of 
drug development and would provide considerable economic benefits to the health 
care system. Additional efforts should be made to pursue this attractive path to 
effective “novel” treatments
PHP99
exPloring aWareness aMong general PuBliC toWards issues related 
to MediCation saFety in Quetta, Pakistan
Jan S.U.1, Iqbal Q.2, Haq N.1, Akhtar M.3
1University of Balochistan, Quetta, Pakistan, 2University of Balochistan, Quetta, Balochistan, 
Pakistan, 3The Islamia University of Bahawalpur, Bahawalpur, Pakistan
objeCtives: The study aims to assess general public awareness towards issues 
related to medication safety in Quetta City, Pakistan. Methods: A cross-sectional 
copayment amount [41.2% with an increase in generic copayment amount; 74.5% 
with an increased in preferred brand copayment amount; 68.5% with an increase 
in non-preferred brand copayment amount]. ConClusions: 12% of continuously 
enroll beneficiaries experienced benefit design changes that could impact prescrip-
tion utlization and adherence measures. Most of them experienced an increased 
in copayment amount, especially for brand name formulary drugs. Benefit design 
should be incorporated into prescription utilization and adherence studies to more 
accurately estimate these measures.
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objeCtives: Several jurisdictions assess the relative clinical effectiveness of new 
therapeutic agents compared to existing products and assign rankings of thera-
peutic improvement. These rankings influence and sometimes determine the 
potential pricing of the product in the respective jurisdiction. This study sought 
to compare the level of therapeutic improvement assessments in three jurisdic-
tions and discuss the parameters leading to any differences observed in level of 
therapeutic improvement rankings. Methods: Efforts were taken to standardize 
the level of therapeutic ranking systems of Canada, France and Germany to have 
comparable levels of therapeutic improvement. We identified 128 unique substances 
reviewed by Canada’s Patented Medicines Price Review Board (PMPRB) between 
2011 and 2013 for which level of therapeutic improvement rankings were assigned. 
Of these, 18 were also reviewed by the Haute-Autorité de Santé (HAS) in France and 
the Federal Joint Committee (GB-A) in Germany. The level of therapeutic improve-
ment rankings were observed in each jurisdiction to assess concurrence among the 
organizations. Results: Preliminary results indicated that there was concurrence 
in the level of therapeutic improvement rankings across the jurisdictions with most 
products receiving low levels of therapeutic improvement (n= 13). ConClusions: 
Overall, concurrence was observed among the agencies’ level of therapeutic 
improvement rankings for the 18 drugs commonly evaluated. Elements such as a 
review’s timing and order, the primary indication and relevant comparators identi-
fied in the therapeutic area by each jurisdiction are important to understand dis-
crepancies in level of therapeutic improvement suggested. Discussion surrounding 
limitations of standardization is necessary to inform results.
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objeCtives: The adoption of elective biomarker tests within US health plans has 
been slow. Without standardized guidelines, payers vary in their coverage policies of 
elective biomarker diagnostics. The aim of this study was to identify factors, includ-
ing the positive predictive value (PPV) of a test, that influence current coverage and 
reimbursement practices of elective biomarker tests amongst US payers. Methods: 
Independent assessments were conducted with two groups of US payers comprised 
of both medical and pharmacy directors from national and regional health plans. 
In October 2013, a focus group of 44 US payers used 7-point Likert scales to evaluate 
hypothetical scenarios involving varying PPVs. In December 2013, 60 US payers were 
surveyed using 7-point Likert scales to categorize factors that influence the coverage 
of elective biomarker diagnostics within their health plans. Elective biomarkers were 
defined as diagnostic tests that are not required as part of the FDA-approved labe-
ling, but may be used in conjunction since evidence demonstrates that test results 
may determine treatment choices and/or outcomes. Chi-squared analyses are in 
progress to observe differences in responses between the two independent payer 
groups, medical and pharmacy directors, as well as national and regional health 
plans. Results: Based on focus group results, 6 (13.6%), 13 (29.5%), 31 (70.5%), and 
40 (90.1%) US payers were more likely to cover biomarker tests as PPV increased from 
20%, 40%, 60% and 80%, respectively. 52 (86.6%) surveyed payers rated the ability to 
predict the effectiveness of a particular therapy, and 42 (70.0%) rated the ability to 
reduce the frequency of other clinical tests as the main factors influencing coverage 
decisions. ConClusions: In lieu of standardized guidelines, this research indicates 
that the more accurate and effective the biomarker test is at determining treatment 
choices and/or outcomes, the more likely it will be covered by US health plans.
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objeCtives: Payers are strongly reluctant to value surrogate endpoints (SEP) as 
they carry substantial uncertainty on the final endpoint. However, it seems that SEP 
are common in payment for performance (P4P) agreements. The objective of this 
project was to Identify the proportion of SEP used in P4P and coverage with evidence 
development (CED). Methods: Market access agreements (MAA) were identified 
from literature review, completed agencies websites, and experts input. P4P and 
CED were selected. Performance endpoints were classified as SEP or hard endpoint 
(HEP). Results: 149 MAA were identified in 13 countries (France, UK, Italy, Sweden, 
Lithuania, Serbia, Slovenia, Germany, Denmark, Portugal, US, Australia, Canada). 39% 
were P4P (individual outcome-based), and 29% were CED (collective outcome-based) 
agreements. The majority of CED endpoints were HEP (92%), such as overall survival, 
decrease in hospitalizations/ prescriptions, delay switch to insulin treatment, real 
world data collection (e.g. long term safety and efficacy, drug conditions of use in 
practice). In contrast, the majority of P4P were SEP (89%), such as assessment of short 
term effectiveness, targeting a short term laboratory value (e.g. decrease in total 
cholesterol levels, HbA1c, etc.). All oncology drugs P4P had SEP performance criteria. 
There were few P4P (14%) with HEP (e.g. fracture, graft rejection for transplant), and 
